PTC Therapeutics, Inc. (PTCT) Dividend History

Company News

• INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR

  Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc. (CAPR) after the company announced that the FDA will hold an advisory committee meeting for its Biologics License Application, causing the stock price to drop.

  GlobeNewswire Inc.

  Featured Companies: CAPR IART
• INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT

  Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. (PTCT) due to concerns about the company's securities fraud or other unlawful business practices. The investigation is related to the Phase 2 PIVOT-HD study of PTC518 (votoplam) in Huntington's disease patients.

  GlobeNewswire Inc.
• RNA Targeting Small Molecule Drug Discovery Research Report 2025 - Global $5.52 Bn Market Trends, Opportunities, and Forecasts, 2020-2030F

  The RNA Targeting Small Molecule Drug Discovery Market is expected to grow significantly, driven by advancements in RNA biology and AI-driven drug discovery. However, the complexity of RNA structures and target specificity pose challenges for the industry.

  GlobeNewswire Inc.
• Evolving Landscape of Mitochondrial Disease Market: Key Insights of Latest Published Report—Leigh Syndrome, Leber’s Hereditary Optic Neuropathy, MELAS Syndrome, and Thymidine Kinase 2 Deficiency | DelveInsight

  The mitochondrial disease market is witnessing steady growth, driven by increasing awareness, improved genetic diagnostics, and advancements in personalized medicine. The article provides insights into the market landscape for Leigh Syndrome, Leber's Hereditary Optic Neuropathy, MELAS Syndrome, and Thymidine Kinase 2 Deficiency.

  GlobeNewswire Inc.
• SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT

  PTC Therapeutics, Inc. (PTCT) faces a potential securities fraud investigation after the European Medicines Agency issued a negative opinion on the renewal of the conditional marketing authorization for its drug Translarna.

  GlobeNewswire Inc.